AU Patent

AU2012296937B2 — Folate conjugates of albumin-binding entities

Assigned to Merck et Cie · Expires 2017-10-12 · 9y expired

What this patent protects

The present invention is directed towards new trifunctional folate-conjugates comprising a folate, an albumin binder and a radionuclide-based therapeutic or diagnostic moiety as well as pharmaceutical compositions thereof, their method of production and their use in diagnostic an…

USPTO Abstract

The present invention is directed towards new trifunctional folate-conjugates comprising a folate, an albumin binder and a radionuclide-based therapeutic or diagnostic moiety as well as pharmaceutical compositions thereof, their method of production and their use in diagnostic and therapeutic medical applications, such as diagnostic nuclear imaging and radionuclide therapy.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012296937B2
Jurisdiction
AU
Classification
—
Expires
2017-10-12
Drug substance claim
No
Drug product claim
No
Assignee
Merck et Cie
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.